a phase I/II trial in 36 patients with heavily-pretreated mCRPC demonstrated a 14.3% objective response rate, a 95.2% disease control rate, and improvements in PSA levels, as well as a manageable safety profile with cytopenias as the most common grade 3 TRAE (CTR20231298) 101
The effectiveness of the product very smooth
(2024) Glucagon-like peptide-1 receptor: mechanisms and advances in therapy Ryan, D.H., Lingvay, I., Deanfield, J
Executive functioning-specific behavioral impairments in a rat model of human third trimester binge drinking implicate prefrontal-thalamo-hippocampal circuitry in Fetal Alcohol Spectrum Disorders
Glutathiosome technology encapsulates 98% purity glutathione in exosomes for deeper skin penetration, combined with triple Vitamin C, 2% Niacinamide, and LHA gentle exfoliation